News | Brachytherapy Systems | October 21, 2015

Long-term Data Supports Xoft System for Early-Stage Breast, Nonmelanoma Skin Cancer

iCAD presents series of clinical studies supporting electronic brachytherapy system for multiple applications at ASTRO 2015

iCAD, Xoft Axxent, electronic brachytherapy, eBx, clinical studies, ASTRO 2015, radiation therapy

Xoft Axxent image courtesy of iCAD Inc.

October 21, 2015 — iCAD Inc. presented updated clinical data, hosted in-booth clinician presentations and showcased the latest in radiation technology at the American Society for Radiation Oncology (ASTRO) meeting in San Antonio, Texas, Oct. 18-21, 2015.

At the meeting, Ajay Bhatnagar, M.D., and Parag Sanghvi, M.D., presented posters with updated data on the use of electronic brachytherapy (eBx) in the treatment of nonmelanoma skin cancer (NMSC). Their data reflect treatment with the Xoft System for a total of 342 patients with 466 NMSC lesions, resulting in excellent cosmesis and few recurrences, with a mean follow-up time of 16.5 months and 11.8 months, respectively.

Alam M. Nisar Syed, M.D., and Adam Dickler, M.D., also presented posters with data supporting use of the Xoft System for the treatment of early-stage breast cancer. Their data reflect treatment of 136 breast cancer lesions with the system, showing positive clinical results, excellent to good cosmesis, few recurrences and a low rate of low-grade adverse events.

Gary Proulx, M.D., medical director, Exeter Hospital Radiation Oncology, clinical associate professor, Massachusetts General Hospital, discussed his clinical experience with intraoperative radiation therapy (IORT) and the Xoft System at the Xoft booth, where the system and its cervical applicator, now commercially available, were on display. Visitors also had an opportunity to see an investigational line of applicators for IORT, shown as works in progress, for the treatment of prostate, head/neck, abdominal and brain cancers, among others.

The Xoft System is an isotope-free radiation treatment that is U.S. Food and Drug Administration (FDA)-cleared, CE marked and licensed in Canada for the treatment of cancer anywhere in the body. It utilizes a proprietary miniaturized X-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The system requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the system makes it easy to treat patients at multiple locations and to easily store the system when not in use.

For more information:,

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init